Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor

Molecular Therapy 2026 Open access

Read full text
Authors: Pablo Tebas, Julie K. Jadlowsky, Yuqi Zhou, María Betina Pampena, George J. Leslie, Nan Liu, Sriram Srivatsa, Colby R. Maldini, Jingxin Wang, Chungdhak Jaming Tsang, Ola Mohamed, Josephine Romano
+13 more Beth Haggarty, Gabriela Plesa, Avery L. Gaymon, Andrea Lynne Brennan, Elizabeth A. Veloso, Bruce L. Levine, Mary E. Putt, Irina M. Kulikovskaya, Vanessa Gonzalez, Joseph A. Fraietta, Michael R. Betts, James A. Hoxie, James L. Riley
DOI: 10.1016/j.ymthe.2026.01.006
Cited by: 0
References: 55

Fields of Study & Subjects

HIV Research and Treatment Immune Cell Function and Interaction Chemokine receptors and signaling

Publication details

Journal / source
Molecular Therapy
Volume
34
Issue
3
Pages
1352–1366
Publication date
10 January 2026
Language
EN